This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Proton Radiation Therapy for Invasive Breast Cancer Following Mastectomy

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Shannon MacDonald, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT01340495
First received: April 20, 2011
Last updated: May 8, 2017
Last verified: May 2017
  Purpose
In this study we are looking at a type of radiation called proton radiation which is known to spare surrounding tissue and organs from radiation. The proton radiation will be delivered using 3D conformal proton radiation or scanned beam/IMPT (Intensity Modulated Proton Radiation Treatment). Proton radiation delivers no dose beyond the region requiring treatment. This may reduce side effects that patients would normally experience with conventional radiation therapy or other means of delivering proton radiation therapy. In this study we are evaluating the effectiveness of using proton radiation delivered to reduce side effects association with radiation treatment.

Condition Intervention
Invasive Breast Cancer Radiation: Proton Radiation

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Study of Proton Radiation Therapy for Invasive Breast Carcinoma Following Mastectomy

Resource links provided by NLM:


Further study details as provided by Shannon MacDonald, MD, Massachusetts General Hospital:

Primary Outcome Measures:
  • To determine the feasibility of using proton radiation for the treatment of invasive breast cancer following mastectomy [ Time Frame: 5 years ]
    To determine the feasibility of using proton radiation for the treatment of invasive breast cancer following mastectomy based on the occurrence of grade 3 or > radiation pneumonitis or any grade 4 toxicity within 3 months after the completion of radiation treatment.


Secondary Outcome Measures:
  • To evaluate the rate and severity of acute skin toxicity [ Time Frame: 5 years ]
  • To evaluate the rate and severity of radiation pneumonitis, a sub-acute toxicity [ Time Frame: 5 years ]
  • To evaluate the rate and severity of late skin toxicity [ Time Frame: 5 years ]
  • To evaluate cosmetic outcome and patient satisfaction with cosmetic outcome [ Time Frame: 5 years ]
  • To evaluate acute and late toxicity of breast reconstruction following proton radiation [ Time Frame: 5 years ]
  • To evaluate the need for unplanned additional surgery for breast reconstruction [ Time Frame: 5 years ]
  • To evaluate early signs of cardiac effects from radiation therapy using Strain Echocardiogram [ Time Frame: 5 years ]
  • Progression free survival [ Time Frame: 5 years ]
    To describe the 5 year progression free survival rate of patients with breast cancer treated with proton radiation


Enrollment: 70
Study Start Date: June 2011
Estimated Study Completion Date: January 2022
Primary Completion Date: April 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Proton Radiation
Radiation therapy with proton beam
Radiation: Proton Radiation
45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks

Detailed Description:

Proton radiation will be delivered daily for approximately 5 1/2 weeks. Patients will be assessed weekly for any side effects they may be experiencing.

Patients will have follow-up visits 4 weeks after proton therapy ends, at 6 months, 12 months, and then every year for up to five years after treatment. Follow-up visits will include a physical examination, radiological imaging (if necessary), echocardiogram, and laboratory tests.

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically confirmed invasive breast cancer confined to the breast and regional lymphatics
  • Completed mastectomy (complete not partial )breast surgery +/- reconstructive surgery
  • Life expectancy > 12 months

Exclusion Criteria:

  • Pregnant or breast-feeding
  • Prior therapeutic radiation > 200 cGy
  • History of a different malignancy unless disease-free for at least 5 years or diagnosed and treated cervical cancer in situ, or basal or squamous cell cancer of the skin
  • Prior investigation chemotherapy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01340495

Locations
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Sponsors and Collaborators
Massachusetts General Hospital
National Cancer Institute (NCI)
Investigators
Principal Investigator: Shannon M MacDonald, M.D. Massachusetts General Hospital
  More Information

Responsible Party: Shannon MacDonald, MD, Attending Radiation Oncologist, Massachusetts General Hospital
ClinicalTrials.gov Identifier: NCT01340495     History of Changes
Other Study ID Numbers: 10-205
Study First Received: April 20, 2011
Last Updated: May 8, 2017

Keywords provided by Shannon MacDonald, MD, Massachusetts General Hospital:
Breast Cancer
Mastectomy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on September 21, 2017